Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03894618 · ClinicalTrials.gov registry record · Phase 1
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
A Phase 1 study, sponsored by Shattuck Labs.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT03894618: Completed Phase 1 study, sponsored by Shattuck Labs.
NCT03894618 is a Phase 1 study that has completed, run by Shattuck Labs. The registered enrollment target is 49 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03894618, a Phase 1 study, has completed, sponsored by Shattuck Labs.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.
Primary Outcome
Number of participants with treatment emergent adverse events
Interventions
- DRUG SL-279252
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2023-05-04 |
| Phase | Phase 1 |
What the finished NCT03894618 record still lists
NCT03894618 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% lower).
The record links to 0 conditions, and to 1 intervention - of which SL-279252 is the first listed.
NCT03894618 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03894618 about?
NCT03894618 is a clinical study titled "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas". This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.
What is the current status of trial NCT03894618?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2019-03-26. Estimated completion is 2023-05-04.
What interventions are being tested in trial NCT03894618?
The interventions under investigation include: SL-279252 (DRUG).
Who is sponsoring clinical trial NCT03894618?
This trial is sponsored by Shattuck Labs, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03894618's enrollment target sits among peer trials
49 1017th of 2000 higher than 976 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI